CD30-positive malignant lymphomas: time for a change of management?

被引：5
|
作者：
Engert, Andreas [1 ,2 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, GHSG, Cologne, Germany
来源：
HAEMATOLOGICA | 2013年 / 98卷 / 08期
关键词：
BRENTUXIMAB VEDOTIN SGN-35; STERNBERG-REED CELLS; HODGKINS LYMPHOMA; DISEASE; POTENT;
D O I：
10.3324/haematol.2013.091561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1168
页数：5
相关论文
共 50 条
  • [1] Challenging CD30-positive lymphomas - Current challenges, new insights and future directions: Joining a conversation on CD30+lymphomas
    Gisselbrecht, Christian
    Borchmann, Peter
    D'Amore, Francesco
    Illidge, Timothy M.
    Zinzani, Pier Luigi
    LEUKEMIA RESEARCH, 2014, 38 (09) : 1003 - 1003
  • [2] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
    Younes, Anas
    Bartlett, Nancy L.
    Leonard, John P.
    Kennedy, Dana A.
    Lynch, Carmel M.
    Sievers, Eric L.
    Forero-Torres, Andres
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1812 - 1821
  • [3] TUMOR-VIRUSES IN CD30-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMAS
    HERBST, H
    STEIN, H
    LEUKEMIA & LYMPHOMA, 1993, 9 (4-5) : 321 - 328
  • [4] Clinical and Immunohistochemical Aspects of Diagnosis of Anaplastic Large Cell CD30-positive Lymphomas
    Kuklin, I. A.
    Kungurov, N. V.
    Kokhan, M. M.
    Kuklina, M. K.
    AKTUELLE DERMATOLOGIE, 2013, 39 (1-2) : 27 - +
  • [5] Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper
    Zinzani, Pier Luigi
    Corradini, Paolo
    Gianni, Alessandro M.
    Federico, Massimo
    Santoro, Armando
    Vitolo, Umberto
    Barosi, Giovanni
    Tura, Sante
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (09): : 507 - 513
  • [6] Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas
    Wagner, Sandro M.
    Melchardt, Thomas
    Egle, Alexander
    Magnes, Teresa
    Skrabs, Cathrin
    Staber, Philipp
    Simonitsch-Klupp, Ingrid
    Panny, Michael
    Lehner, Barbara
    Greil, Richard
    Keil, Felix
    Jager, Ulrich
    Sillaber, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (03) : 251 - 258
  • [7] SIALOSYLATED LEWIS(X) EXPRESSION IN CD30-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMAS
    KASAI, K
    SATO, Y
    KUWAO, S
    KAWAKUBO, Y
    INOUE, H
    KAMEYA, T
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 119 (02) : 87 - 90
  • [8] PERSISTENCE OF CD30 EXPRESSION IN CD30-POSITIVE LYMPHOMAS FOLLOWING TREATMENT WITH BRENTUXIMAB VEDOTIN (SGN-35)
    Chen, W.
    Nathwani, N.
    Forman, S.
    Popplewell, L.
    Krishnan, A.
    Gomez, C.
    Karanes, C.
    Smith, E.
    Farol, L.
    Thomas, S.
    Kim, Y.
    HAEMATOLOGICA, 2012, 97 : 81 - 82
  • [9] HIGH-INCIDENCE OF EBV GENOME IN CD30-POSITIVE NON-HODGKINS-LYMPHOMAS
    KANAVAROS, P
    JIWA, NM
    DEBRUIN, PC
    VANDERVALK, P
    NOORDUYN, LA
    VANHEERDE, P
    GORDIJN, R
    HORSTMAN, A
    MULLINK, R
    WILLEMZE, R
    WALBOOMERS, JMM
    MEIJER, CJLM
    JOURNAL OF PATHOLOGY, 1992, 168 (03): : 307 - 315
  • [10] CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
    Bisig, Bettina
    de Reynies, Aurelien
    Bonnet, Christophe
    Sujobert, Pierre
    Rickman, David S.
    Marafioti, Teresa
    Delsol, Georges
    Lamant, Laurence
    Gaulard, Philippe
    de Leval, Laurence
    HAEMATOLOGICA, 2013, 98 (08) : 1250 - 1258
12345